Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tvardi Therapeutics
Biotech
Tvardi's STAT3 inhibitor flunks IPF trial amid high dropout rate
The biotech reported high dropout rates and placebolike efficacy in a phase 2 trial of its idiopathic pulmonary fibrosis prospect.
Nick Paul Taylor
Oct 13, 2025 9:25am
Tvardi to go public via merger with cash-strapped Cara
Dec 18, 2024 10:37am
Biotech incubator Sporos' new CEO arrives from Ovid
Sep 29, 2021 12:23pm
Tvardi stacks the bank with $74M series B for STAT3 inhibitor
Jun 23, 2021 8:00am
